Medicine and Dentistry
Alanine Aminotransferase
11%
Antibody
31%
Antigen
9%
Antivirus Agent
26%
Association
27%
Boron Neutron Capture Therapy
18%
Cells
36%
Chemotherapeutic Agent
10%
Chronic Hepatitis B
65%
Combination Therapy
49%
CTLA-4
26%
Death
19%
Development
23%
Drug
10%
Ex Vivo
14%
Fibrosis
9%
Hepatitis
31%
Hepatitis B
12%
Hepatitis B Antigen
40%
Hepatitis B Core Antigen
31%
Hepatitis B Virus
75%
Hepatitis B(e) Antigen
34%
Hepatitis C Virus
31%
Hepatocellular Carcinoma
12%
Immunosuppressive Treatment
21%
Infection
11%
Inpatient
100%
Ligand
12%
Ligation
10%
Liver
15%
Liver Cancer
17%
Liver Transplantation
31%
Liver Tumor
14%
Neoplasm
36%
Nonalcoholic Fatty Liver
21%
Nucleotide
26%
Patient
70%
Peginterferon
31%
Plasmacytoid Dendritic Cell
14%
Primary Biliary Cirrhosis
31%
Regulatory T Cell
21%
Statin
31%
Survival
33%
T Cell
14%
Tenofovir Disoproxil
23%
Therapeutic Procedure
79%
Ursodeoxycholic Acid
31%
Viral Clearance
17%
Virus DNA
20%
Virus RNA
9%
Immunology and Microbiology
Adaptive Immune System
10%
Antigen
9%
Antiviral Immune Response
10%
Association
6%
Blocking Antibody
5%
Capsid
6%
CD4
12%
Cell Function
5%
Cells
12%
Clearance
5%
CTLA-4
26%
Cytokine Production
5%
Dendritic Cell Function
10%
Development
31%
DNA Virus
9%
Gene
12%
Genotype
6%
Glucocorticoid
26%
HBcAg
31%
HBsAg
26%
Hepatitis B
99%
Hepatitis B Virus
55%
Hepatitis B Virus
50%
Hepatitis B(e) Antigen
34%
Hepatitis C
23%
Hepatitis C Virus
38%
Human
8%
Immunity
5%
Immunosuppression
17%
Incidence
15%
Inflammation
42%
Innate Immune System
10%
Liver
92%
Low Drug Dose
5%
Molecule
10%
Monospecific Antibody
31%
Nomenclature
21%
Pegylated Interferon
31%
Plasmacytoid Dendritic Cell
14%
Protein Targeting
21%
Regulatory T Cell
66%
Sex
7%
Time
11%
Tumor Necrosis Factor Receptor
26%
Viral Disease
29%
Virus
10%
Virus Antigen
10%
Virus Core
21%
Nursing and Health Professions
Alanine
31%
Alanine Aminotransferase
11%
Chronic Hepatitis B
42%
Chronic Hepatitis C
7%
Combination Therapy
24%
Deterioration
18%
Diagnosis
7%
DNA
23%
Enalapril Maleate
23%
Hepatitis B
8%
Hepatitis B Surface Antigen
28%
Hepatitis B(e) Antigen
15%
Hepatitis C
7%
Incidence
15%
Inpatient
15%
Male
7%
Monitoring
7%
Patient
56%
Placebo
9%
Prediction
7%
Proportional Hazards Model
7%
Relapse
16%
Retreatment
22%
Tenidap
7%
Time
11%
Viral Clearance
17%
Virus DNA
6%
Virus RNA
6%